The US IPO market seems to be hitting the pause button to recognize the holidays, with no companies on the calendar to price in the coming week. However, there is still a possibility that certain SPACs or Chinese deals launch early in the week to price by...read more
Six IPOs raised a combined $1.7 billion this past week, all of which began trading on Friday in the single busiest day of 2020 so far. API platform Agora (API) skyrocketed 153% in the best first day pop since 2019 IPO Beyond Meat (BYND)....read more
PolyPid, a Phase 3 biotech developing extended-release drugs to prevent surgical site infections, raised $60 million by offering 3.8 million shares at $16, within the range of $15 to $17. The company offered 625,000 more shares than anticipated. Insiders...read more
PolyPid, a Phase 3 biotech developing extended-release drugs to prevent surgical site infections, announced terms for its IPO on Monday. This is PolyPid's third attempt to go public. It last filed in February 2018 but withdrew a month later, citing market...read more
US IPO Week Ahead: Time off for the Holidays
The US IPO market seems to be hitting the pause button to recognize the holidays, with no companies on the calendar to price in the coming week. However, there is still a possibility that certain SPACs or Chinese deals launch early in the week to price by...read more
US IPO Weekly Recap: Agora pops 153% while Albertsons falls flat in a 6 IPO week
Six IPOs raised a combined $1.7 billion this past week, all of which began trading on Friday in the single busiest day of 2020 so far. API platform Agora (API) skyrocketed 153% in the best first day pop since 2019 IPO Beyond Meat (BYND)....read more
Surgical infection biotech PolyPid prices upsized US IPO at $16 midpoint
PolyPid, a Phase 3 biotech developing extended-release drugs to prevent surgical site infections, raised $60 million by offering 3.8 million shares at $16, within the range of $15 to $17. The company offered 625,000 more shares than anticipated. Insiders...read more
Surgical infection biotech PolyPid sets terms for $50 million US IPO
PolyPid, a Phase 3 biotech developing extended-release drugs to prevent surgical site infections, announced terms for its IPO on Monday. This is PolyPid's third attempt to go public. It last filed in February 2018 but withdrew a month later, citing market...read more